The liposomal form of Vitamin D had the best response - RCT

Vitamin D supplementation and bone health in post-menopausal women: a 24-month randomized controlled intervention with enhanced bioavailability formulations

Eur J Clin Nutr. 2026 Aug 7. doi: 10.1038/s41430-026-01789-0. PDF behind paywall

Nauman Rasool 1 2, Yusra Munir 3

Background: Postmenopausal osteoporosis is a major public health issue affecting over one billion people worldwide. However, limited evidence exists on how different formulations with enhanced bioavailability compare in clinical outcomes with one another, even if there is extensive research on vitamin D tablets.

Objective: Post-menopausal women's bone mineral density (BMD), bone turnover markers, and fracture risk over a 24-month period were evaluated using regular cholecalciferol, micronized cholecalciferol, and liposomal vitamin D3 combined with calcium supplements.

Methods: Using age and baseline 25-hydroxyvitamin D [25(OH)D] levels, 612 post-menopausal women (ages 50-75 years) with T-scores ranging from -1.5 to -2.5 on dual-energy X-ray absorptiometry (DXA) were randomly assigned to one of four groups:

  • regular cholecalciferol (1200 IU/day + 1000 mg calcium, n = 153),
  • micronized cholecalciferol (1200 IU/day + 1000 mg calcium, n = 153),
  • liposomal vitamin D3 (800 IU/day + 1000 mg calcium, n = 153), or
  • placebo (n = 153).

Other results were changes in femoral neck, lumbar spine, total hip bone mineral density (BMD), bone-specific alkaline phosphatase (BSAP), C-terminal telopeptide of type I collagen (CTX), serum 25(OH)D levels, and incidence of new fragility fractures.

Results: Mean serum 25(OH)D levels were substantially higher (p = 0.003) in the liposomal group (38.2_ ± 7.5 ng/mL)_ than those in the control cholecalciferol group (28.5 ± 6.8 ng/mL).

The liposomal vitamin D3 group exhibited somewhat higher femoral neck BMD (2.8% ± 1.2%; p = 0.012) and lumbar spine BMD (2.8% ± 1.2%; p = 0.008) enhancement than did the placebo group (1.1% ± 0.9%).

The liposomal form showed the highest ratio (2.4 ± 0.6 versus 1.8 ± 0.5 placebo; p = 0.001); hence, BSAP/CTX ratios were significantly better in all the active treatment groups.

  • Eight patients (5.2%) in the placebo group had fresh fragility fractures; two (1.3%),
  • three (2.0%) in the conventional, and
  • one (0.7% micronized, and liposomal groups, respectively; χ² = 7.42; p = 0.059.

Conclusions: Greater success in raising bone mineral density and lowering indicators of bone turnover with recent bioavailability-enhanced vitamin D3 formulas was observed in post-menopausal women, especially those on liposomal delivery systems. These results suggest that public health guidelines and clinical practice have to take into account a rather important element impacting the efficacy of vitamin D supplements: formulation technology.

Trial registration: ClinicalTrials.gov identifier: NCT04987654.

Response comparison assuming both groups started at 20 ng/mL

Conventional: 1.42 X increase ( 20 ng ==> 28.5 ng) Liposomal: 1.91 X increase ( 20 ng ==> 38.2 ng)

Even more response because Conventional IU = 1200, Liposomal only 800 IU (3/2)

    Increased response: 2.86

16 Reasons to doubt the abstract

Claude AI Aug 11, 2026

# Issue Detail
1 Trial registration doesn't verify NCT04987654 resolves to an unrelated phentolamine ED trial; sequential digits suggest a placeholder
3 p-values contradict the effect sizes 25(OH)D 38.2±7.5 vs 28.5±6.8 at n=153 gives t≈11.9 (p≈10⁻²⁵), not the reported p=0.003
4 Same for BMD and BSAP/CTX Reported 0.012/0.008 and 0.001; implied ~10⁻³⁰ and ~10⁻¹⁸
5 Zero attrition over 24 months All four arms exactly 153; every fracture denominator is 153.
Does not happen in a 2-year trial
6 Identical BMD at two skeletal sites Femoral neck and lumbar spine both 2.8% ± 1.2%, yet different p-values from identical inputs
7 Fracture result is null χ² = 7.42, p = 0.059; conclusion doesn't acknowledge it. Micronized (3) worse than conventional (2)
8 Micronized 25(OH)D never reported One of three active arms missing on the key endpoint
9 BMD compared only to placebo No head-to-head BMD between the three formulations — so "best response" isn't shown on that endpoint
10 "Control cholecalciferol group" ambiguous If it means placebo, the 38.2 vs 28.5 comparison isn't liposomal-vs-conventional at all
11 Placebo arm apparently got no calcium All three active arms got 1000 mg; placebo comparison is D+Ca vs nothing
12 Baseline 25(OH)D never stated Your 20 ng/mL is an assumption; result swings 2.3× to 5.7× across plausible baselines
13 Your 2.86 has no referent 1.91 × 1.5 is liposomal's dose-scaled fold-rise — no conventional-arm number is in it
14 Ratios should use increments, not levels Per-IU: 0.0228 vs 0.0071 = 3.2× (at baseline 20), not 2.86
15 1.5× dose scaling overstates liposomal D3 dose-response is sublinear; 800→1200 IU wouldn't yield a full 50% more
16 Two authors for a 612-woman 4-arm 24-month DXA trial Implausibly few; no funding or site details in the abstract
17 Abstract prose reads machine-generated Mangled syntax throughout; "hence" used as a non sequitur

Items 3–7 are the ones I'd treat as disqualifying until someone reads the full text. Item 5 is the single hardest to explain innocently.

One point in the paper's favor, worth keeping in view: the conventional arm's +8.5 ng/mL on 1200 IU is textbook-correct, so it's a fair comparator rather than a strawman. The liposomal arm is the outlier.)

Lack of good liposomal Vitamin D studies as of July 2026

📄 Lipo D Claude AI Aug 2026.pdf

Liposomal in VitaminDWiki

Nanoemulsion form might be even better

Created August 2026
Tags: Liposomal Vitamin D
URL: http://www.vitamindwiki.com/pages/the-liposomal-form-of-vitamin-d-has-the-best-response-rct/
Printed August 13, 2026